Omnicare (NYSE: OCR ) is expected to report Q3 earnings around Oct. 25. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Omnicare's revenues will contract -0.2% and EPS will increase 29.6%.
The average estimate for revenue is $1.54 billion. On the bottom line, the average EPS estimate is $0.70.
Last quarter, Omnicare chalked up revenue of $1.54 billion. GAAP reported sales were 1.3% lower than the prior-year quarter's $1.56 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.63. GAAP EPS were $0.17 for Q2 compared to -$0.01 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 23.9%, 230 basis points better than the prior-year quarter. Operating margin was 9.2%, 150 basis points better than the prior-year quarter. Net margin was 1.2%, 130 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $6.21 billion. The average EPS estimate is $2.86.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 226 members out of 246 rating the stock outperform, and 20 members rating it underperform. Among 83 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 79 give Omnicare a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Omnicare is outperform, with an average price target of $37.28.
- Add Omnicare to My Watchlist.